Citadel Advisors
LABU icon

Citadel Advisors’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History

Citadel Advisors’s Portfolio LABU Stock Details LABU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-91,850
Closed -$12.6M – 13457
2025
Q3 		$8.6M Buy
+91,850
New +$6.49M ﹤0.01% 3488
2025
Q1 		– Sell
-120,500
Closed -$10.3M – 15096
2024
Q4 		$10.8M Buy
120,500
+117,965
+4,653% +$13.9M ﹤0.01% 2885
2024
Q3 		$326K Sell
2,535
-56,001
-96% -$7.31M ﹤0.01% 9156
2024
Q2 		$6.64M Sell
58,536
-20,509
-26% -$2.2M ﹤0.01% 3326
2024
Q1 		$10.5M Sell
79,045
-7,522
-9% -$982K ﹤0.01% 2895
2023
Q4 		$10.6M Buy
86,567
+29,688
+52% +$2.27M ﹤0.01% 2769
2023
Q3 		$4.33M Sell
56,879
-31,214
-35% -$3.2M ﹤0.01% 3896
2023
Q2 		$10.4M Buy
88,093
+10,433
+13% +$1.3M ﹤0.01% 2619
2023
Q1 		$7.63M Sell
77,660
-24,335
-24% -$3.3M ﹤0.01% 3164
2022
Q4 		$14.4M Buy
101,995
+78,868
+341% +$11M ﹤0.01% 2344
2022
Q3 		$3.24M Sell
23,127
-1,965
-8% -$360K ﹤0.01% 4651
2022
Q2 		$3.38M Sell
25,092
-8,478
-25% -$1.44M ﹤0.01% 4545
2022
Q1 		$10.5M Buy
33,570
+14,877
+80% +$5.61M ﹤0.01% 2861
2021
Q4 		$13.5M Buy
18,693
+14,970
+402% +$14.3M ﹤0.01% 2574
2021
Q3 		$4.12M Buy
3,723
+2,812
+309% +$3.46M ﹤0.01% 4683
2021
Q2 		$1.34M Buy
911
+369
+68% +$512K ﹤0.01% 7580
2021
Q1 		$856K Sell
542
-2,907
-84% -$6.81M ﹤0.01% 8489
2020
Q4 		$6.93M Buy
3,449
+1,379
+67% +$2.2M ﹤0.01% 3137
2020
Q3 		$2.22M Sell
2,070
-2,090
-50% -$2.4M ﹤0.01% 4531
2020
Q2 		$4.94M Sell
4,160
-5,101
-55% -$4.42M ﹤0.01% 3095
2020
Q1 		$4.17M Buy
9,261
+4,005
+76% +$3.64M ﹤0.01% 2966
2019
Q4 		$6.04M Sell
5,256
-3,500
-40% -$3.14M ﹤0.01% 2847
2019
Q3 		$5.41M Buy
8,756
+3,868
+79% +$3.21M ﹤0.01% 3002
2019
Q2 		$4.91M Buy
4,888
+4,704
+2,557% +$4.56M ﹤0.01% 3115
2019
Q1 		$220K Sell
184
-1,221
-87% -$1.27M ﹤0.01% 8076
2018
Q4 		$923K Buy
1,405
+1,253
+824% +$1.31M ﹤0.01% 5437
2018
Q3 		$284K Buy
+152
New +$299K ﹤0.01% 7657
2018
Q2 		– Sell
-389
Closed -$685K – 9083
2018
Q1 		$618K Sell
389
-1,406
-78% -$2.62M ﹤0.01% 5533
2017
Q4 		$2.8M Buy
+1,795
New +$2.75M ﹤0.01% 3194
2017
Q2 		– Sell
-458
Closed -$462K – 7807
2017
Q1 		$437K Buy
+458
New +$408K ﹤0.01% 5246
2016
Q4 		– Sell
-457
Closed -$343K – 7583
2016
Q3 		$446K Sell
457
-732
-62% -$604K ﹤0.01% 5032
2016
Q2 		$671K Buy
+1,189
New +$745K ﹤0.01% 4093
2016
Q1 		– Sell
-70
Closed -$118K – 7408
2015
Q4 		$118K Buy
+70
New +$113K ﹤0.01% 6506

Other funds holding LABU

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
MIG
McGuire Investment Group Wakefield, Rhode Island $885M AUM 47.78% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $84.4B AUM 52.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Citadel Advisors's LABU Position: Q4 2025 in Review

Citadel Advisors sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q4 2025, closing a stake of 91,850 shares — an estimated $12.6M sold.

Citadel Advisors first reported a position in LABU in Q4 2015 and held it in 33 quarters. The position peaked at $14.4M in Q4 2022. 40 funds tracked by Wall St. Rank hold LABU as of Q4 2025.

  • Citadel Advisors reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 91,850 Direxion Daily S&P Biotech Bull 3X ETF shares in Q4 2025, an estimated $12.6M.
  • Citadel Advisors first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q4 2015 and held it in 33 quarters.
  • Citadel Advisors's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $14.4M in Q4 2022.
  • 40 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.